• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Surmodics’ DCB shown non-inferior to Medtronic’s In.Pact Admiral

January 26, 2021 By Sean Whooley

SurModicsSurmodics (NSDQ:SRDX) announced data showing that its SurVeil drug-coated balloon is non-inferior to Medtronic’s In.Pact Admiral.

Eden Prairie, Minn.-based Surmodics’ 12-month data from the Transcend clinical trial, presented at the Leipzig Interventional Course 2021 virtual event, revealed primary results that found the SurVeil DCB is non-inferior to In.Pact Admiral in both safety and efficacy while delivering a “substantially lower” drug dose, according to a news release.

Transcend is a global, multi-center, randomized, controlled clinical trial with 1:1 randomization to SurVeil or In.Pact Admiral in patients with symptomatic femoropopliteal artery disease. Both DCBs use coatings with paclitaxel — a controversial drug that could cause a higher risk for death — although In.Pact Admiral has a 75% higher drug load of paclitaxel than SurVeil, Surmodics said.

The primary efficacy endpoint for the trial was primary patency — defined as a composite of freedom from clinically-driven target lesion revascularization and binary restenosis — at 12 months. The primary safety endpoint was freedom from device- or procedure-related death through 30 days and freedom from above-ankle amputation and clinically-driven target vessel revascularization within 12 months.

SurVeil was found to be non-inferior to In.Pact Admiral in both the primary safety and primary efficacy endpoints. In total, 91.7% of subjects (222 patients) reached the safety endpoints for SurVeil, compared to 89.6% in the In.Pact Admiral arm (224 patients). SurVeil saw 81.7% efficacy compared to 85.9% efficacy in the In.Pact Admiral arm.

“We are grateful to Dr. Rosenfield, co-principal investigators Dr. Marianne Brodmann and Dr. William Gray and all the physicians and coordinators for their commitment to this important first of its kind clinical trial during a worldwide pandemic,” Surmodics president & CEO Gary Maharaj said in the release. “Transcend demonstrates that achieving clinically safe and effective outcomes with a substantially lower dose of Paclitaxel is achievable with the SurVeil DCB, which sets a new standard with its proprietary coating technology and therapeutic choice for physicians and the patients that they treat.”

Needham analyst Mike Matson wrote that analysts expect the Transcend trial to lead to FDA approval and subsequent commercialization for SurVeil, followed by added revenue for Surmodics. They expect FDA approval as soon as late 2021.

Additionally, Matson’s conservative estimate sees SurVeil as potentially worth around $10 per share to Surmodics, leading Needham to list the company as a “buy” option.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: Medtronic, Surmodics

IN CASE YOU MISSED IT

  • BriaCell Therapeutics closes $25M offering
  • ICU Medical dips despite Street-beating Q4
  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS